Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging.

Tytuł:
Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging.
Autorzy:
Heusner TA; Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45122, Essen, Germany. />Kuemmel S
Koeninger A
Hamami ME
Hahn S
Quinsten A
Bockisch A
Forsting M
Lauenstein T
Antoch G
Stahl A
Źródło:
European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2010 Jun; Vol. 37 (6), pp. 1077-86. Date of Electronic Publication: 2010 Mar 04.
Typ publikacji:
Clinical Trial; Comparative Study; Journal Article
Język:
English
Imprint Name(s):
Original Publication: Berlin : Springer-Verlag Berlin, 2002-
MeSH Terms:
Fluorodeoxyglucose F18*
Breast Neoplasms/*diagnosis
Breast Neoplasms/*pathology
Magnetic Resonance Imaging/*methods
Positron-Emission Tomography/*methods
Tomography, X-Ray Computed/*methods
Adult ; Aged ; Breast Neoplasms/diagnostic imaging ; Diffusion ; Humans ; Magnetic Resonance Imaging/standards ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Staging ; Positron-Emission Tomography/standards ; Prospective Studies ; Reference Standards ; Tomography, X-Ray Computed/standards ; Whole Body Imaging
References:
Cancer Imaging. 2006 Sep 13;6:135-43. (PMID: 17015238)
Ann Surg. 1983 Mar;197(3):276-83. (PMID: 6830335)
J Magn Reson Imaging. 2006 Aug;24(2):319-24. (PMID: 16786565)
Rofo. 2008 Apr;180(4):302-9. (PMID: 18370348)
Ann Nucl Med. 2007 Jun;21(4):209-15. (PMID: 17581719)
Nihon Hinyokika Gakkai Zasshi. 2008 Nov;99(7):737-41. (PMID: 19068691)
Eur J Cardiothorac Surg. 2009 Apr;35(4):706-10; discussion 710-1. (PMID: 19216085)
Adv Exp Med Biol. 2007;608:1-22. (PMID: 17993229)
J Thorac Cardiovasc Surg. 2008 Apr;135(4):816-22. (PMID: 18374761)
Radiology. 2008 Aug;248(2):643-54. (PMID: 18539889)
Cancer. 1987 Feb 15;59(4):682-7. (PMID: 3802027)
Top Magn Reson Imaging. 2008 Jun;19(3):171-6. (PMID: 18941397)
Eur J Radiol. 2008 Sep;67(3):440-7. (PMID: 18430538)
AJR Am J Roentgenol. 2007 Jun;188(6):1622-35. (PMID: 17515386)
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. (PMID: 19474385)
Radiat Med. 2008 May;26(4):222-6. (PMID: 18509722)
Semin Neurol. 2008 Sep;28(4):395-406. (PMID: 18843569)
Magn Reson Med Sci. 2007;6(3):147-55. (PMID: 18037795)
Radiat Med. 2007 Jun;25(5):218-23. (PMID: 17581710)
Int J Clin Pract. 2001 Dec;55(10):676-9. (PMID: 11777292)
Eur J Nucl Med Mol Imaging. 2003 Apr;30(4):588-96. (PMID: 12582813)
Eur J Nucl Med Mol Imaging. 2009 Oct;36(10 ):1543-50. (PMID: 19415270)
Br J Radiol. 2008 Sep;81(969):743-8. (PMID: 18508873)
J Thorac Oncol. 2008 Apr;3(4):358-64. (PMID: 18379353)
J Magn Reson Imaging. 2008 Nov;28(5):1157-65. (PMID: 18972357)
NMR Biomed. 1995 Nov-Dec;8(7-8):289-96. (PMID: 8739267)
Eur J Radiol. 2010 Feb;73(2):294-9. (PMID: 19181468)
Radiology. 2007 Feb;242(2):360-85. (PMID: 17255408)
Cancer. 2006 Dec 1;107(11):2545-51. (PMID: 17063499)
Radiology. 2004 Mar;230(3):879-85. (PMID: 14764889)
Ai Zheng. 2007 Feb;26(2):168-71. (PMID: 17298747)
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. (PMID: 18287387)
NMR Biomed. 2009 Jan;22(1):104-13. (PMID: 18384182)
Breast Cancer. 2008;15(3):224-30. (PMID: 18465196)
J Comput Assist Tomogr. 2009 Jan-Feb;33(1):63-9. (PMID: 19188787)
Eur J Radiol. 2009 Dec;72(3):381-7. (PMID: 18995981)
Radiology. 2008 Dec;249(3):1017-25. (PMID: 18849502)
Surg Today. 2006;36(12):1047-52. (PMID: 17123131)
BMC Cancer. 2009 Jan 14;9:18. (PMID: 19144163)
J Magn Reson Imaging. 2009 Feb;29(2):336-40. (PMID: 19161185)
J Nucl Med. 2008 Aug;49(8):1215-22. (PMID: 18632831)
Radiographics. 2007 Oct;27 Suppl 1:S215-29. (PMID: 18180228)
Radiology. 2009 May;251(2):398-407. (PMID: 19276322)
Radiologia. 2007 Nov-Dec;49(6):407-15. (PMID: 18021670)
Substance Nomenclature:
0Z5B2CJX4D (Fluorodeoxyglucose F18)
Entry Date(s):
Date Created: 20100306 Date Completed: 20100809 Latest Revision: 20181113
Update Code:
20240104
DOI:
10.1007/s00259-010-1399-z
PMID:
20204355
Czasopismo naukowe
Purpose: The aim of the study was to prospectively compare the diagnostic value of whole-body diffusion-weighted imaging (DWI) and FDG PET/CT for breast cancer (BC) staging.
Methods: Twenty BC patients underwent whole-body FDG PET/CT and 1.5-T DWI. Lesions with qualitatively elevated signal intensity on DW images (b = 800 s/mm(2)) were rated as suspicious for tumour and mapped to individual lesions and different compartments (overall 552 lesions). The apparent diffusion coefficient (ADC) value was determined for quantitative evaluation. Histopathology, MRI findings, bone scan findings, concordant findings between FDG PET/CT and DWI, CT follow-up scans and plausibility served as the standards of reference defining malignancy.
Results: According to the standards of reference, breasts harboured malignancy in 11, regional lymph nodes in 4, M1 lymph nodes in 3, bone in 7, lung in 2, liver in 3 and other tissues in 3 patients. On a compartment basis, the sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) for the detection of malignancies were 94, 99, 98, 97 and 98% for FDG PET/CT and 91, 72, 76, 50 and 96% for DWI, respectively. Of the lesions seen on DWI only, 348 (82%) turned out to be false-positive compared to 23 (11%) on FDG PET/CT. The average lesion ADC was 820 +/- 300 with true-positive lesions having 929 +/- 252 vs 713 +/- 305 in false-positive lesions (p < 0.0001).
Conclusion: Based on these initial data DWI seems to be a sensitive but unspecific modality for the detection of locoregional or metastatic BC disease. There was no possibility to quantitatively distinguish lesions using ADC. DWI alone may not be recommended as a whole-body staging alternative to FDG PET(/CT). Further studies are necessary addressing the question of whether full-body MRI including DWI may become an alternative to FDG PET/CT for whole-body breast cancer staging.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies